Advertisement


Yelena Y. Janjigian, MD, FASCO, on Safety Results From DESTINY-Gastric03

ASCO 2026

Advertisement

Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzumab deruxtecan-nxki–based regimens in advanced HER2-expressing gastric cancer, gastroesophageal adenocarcinoma, and esophageal carcinoma (Abstract 4002).



Related Videos

Bladder Cancer

Xin Gao, MD, on Advanced or Metastatic Urothelial Carcinoma: LY4101174

Xin Gao, MD, of Massachusetts General Hospital and Harvard Medical School, discusses initial results from the phase I EXCEED trial of LY4101174, a Nectin-4–targeting antibody-drug conjugate, for patients with advanced or metastatic urothelial carcinoma (Abstract 4517).

Breast Cancer

Jame Abraham, MD, FACP, on First Results of the OPTIMA Trial in Breast Cancer: Expert Perspective

Jame Abraham, MD, FACP, of Cleveland Clinic, offers his thoughts on findings from OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), an international randomized controlled trial comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment in mostly node-positive patients with high clinical risk ER-positive HER2-negative early breast cancer (Abstract 500). 

Hepatobiliary Cancer
Geriatric Oncology

Mohammed Al-Jumayli, MD, on a Digital Prehabilitation Model in Older Adults Undergoing Hepatobiliary Cancer Surgery

Mohammed Al-Jumayli, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the effects of the use of a multimodal, digitally supported prehabilitation program among adults aged 65 years and older undergoing surgery for hepatobiliary cancer; the model was associated with favorable short-term functional performance signals and high levels of engagement (Abstract 12039). 

Breast Cancer

Nicholas C. Turner, MD, PhD, on ER-Positive, HER2-Negative Advanced Breast Cancer: persevERA BC Trial

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, Institute of Cancer Research, discusses results from the primary analysis of the persevERA BC trial, which investigated giredestrant plus palbociclib vs letrozole plus palbociclib as first-line therapy in patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (Abstract LBA1006).

Prostate Cancer

Mary-Ellen Taplin, MD, FASCO, on High-Risk Localized or Locally Advanced Prostate Cancer: PROTEUS Trial

Mary-Ellen Taplin, MD, FASCO, of Dana-Farber Cancer Institute, presents the final analysis of the phase III PROTEUS study, which looked at perioperative (neoadjuvant and adjuvant) apalutamide plus androgen-deprivation therapy (ADT) vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer (Abstract LBA1).

Advertisement

Advertisement




Advertisement